FDA looks at calcium salt bone void filler:
This article was originally published in Clinica
Executive Summary
The US FDA has proposed to classify resorbable calcium salt bone void filler used to fill bony voids or gaps caused by trauma or surgery into class II special controls (a guidance document has been released at the same time). The reclassification applies to those fillers that are not intrinsic to the stability of the bony structure. The product was on the market prior to 1976 when the amendments to US Food and Drug law establishing medical device regulation went into effect and therefore was allowed to remain on the market until it could be classified by the agency. The FDA inadvertently left the product off the list when it classified other pre-amendment products in 1987. Comments are due on May 8.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.